Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Thrombocytosis 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Hypereosinophilic Syndrome 1Dendritic Cell Sarcoma, Interdigitating 1Acromesomelic dysplasia, Maroteaux type 1

Interventions

pembrolizumab 9Pemetrexed 7Cyclophosphamide 6Nivolumab 5Ipilimumab 5Cisplatin 5Carboplatin 5fludarabine 4Drug Therapy 2Bevacizumab 2tremelimumab 1tocilizumab 1tazemetostat 1spartalizumab 1sotorasib 1rebastinib 1poly ICLC 1pevonedistat 1osimertinib 1milademetan 1fludarabine phosphate 1epacadostat 1durvalumab 1defactinib 1atezolizumab 1aldesleukin 1Vorinostat 1Thiostrepton 1Tablets 1Plicamycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Mesothelioma × pevonedistat × Clear all
NCT03319537 2024-05-23

Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Terminated
9 enrolled 9 charts
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡